A recent report published by Infinium Global Research on childhood absence epilepsy treatment market provides in-depth analysis of segments and sub-segments in the global as well as regional childhood absence epilepsy treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional childhood absence epilepsy treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global childhood absence epilepsy treatment market. According to the report, the global childhood absence epilepsy treatment market is projected to grow at a CAGR of 5.1% over the forecast period of 2019-2025.

Market Insight

The childhood absence epilepsy (CAE) is a common type of problem in childhood and adolescence. It is caused by several different factors that impact the functioning of the brain. The general causes of epilepsy are a genetic problem or acquired or sometimes both are responsible for it. The causes of childhood absence epilepsy change as per the age of the disease grow in the person. The patients suffering from this type of problem suffer from the absence seizure. The absence seizure is a condition in which a person appears as staring at someone or something, but in reality s/he does not aware/responsive to that situation. Further, the patient eye rolls up suddenly or eye blinks. some patients start mouth chewing during this situation. This influence of seizure lasts for the 10 seconds after this patient resumes his normal activities.

There is generally two types of seizure atypical absence seizure and typical absence seizure. The atypical absence seizure often occurs with other types of seizure. Further, this mainly occurs to those children, who are suffering from neurologic disabilities. The typical absence seizure is short duration epileptic seizure i.e. sudden start and termination of the disease. This disease is a cluster of clinico-EEG manifestations, which would be syndrome related. It is a pharmacologically unique disease compared to other types of seizure problem.

As per the Epilepsy Foundation Michigan, the epilepsy is the fourth most common neurological disorder in the United States after migraine, stroke, and Alzheimer’s disease. About 1.2% of Americans have some form of epilepsy, and nearly four percent (1 in 26) population are expected to develop epilepsy at some point in their lives. The number of Americans who have epilepsy is greater than the number who have multiple sclerosis, Parkinson’s disease, and cerebral palsy combined. Further, 10% of Americans are estimated to have at least one seizure at some point in their lives. Moreover, the epilepsy is prevalent among other disability groups in the U.S, such as autism (25.5%), cerebral palsy (13%), Down syndrome (13.6%), and intellectual disability (25.5%). For people with both cerebral palsy and intellectual disability, the prevalence of epilepsy is 40%.

As per the Morbidity and Mortality Weekly Report, August 2017, approximately 3 million adults and 4,70,000 children had active epilepsy problem in 2015. Around 1.2% of the U.S. population is suffering from the epilepsy problem. It estimated that the number of patients suffering from active epilepsy problem is increasing every year in the United States, owing to the population growth. The estimated number of patients suffering from active epilepsy in the United States range from 5,900 in Wyoming to 427,700 in California. Further, as per the Centers for Disease Control and Prevention, U.S. the number of patients with active epilepsy rose from 2.3 million in 2010 to 3 million in 2015. Additionally, the number of children with the condition increased from 450,000 in 2007 to 470,000 in 2015.

The North America is the leading market of the childhood absence epilepsy treatment market, owing to growing awareness among the parents, and governmental support to provide long treatment through government funded healthcare scheme. Additionally, the continuous growing population and the presence of leading medical pharmaceutical companies in this region are boosting the growth of childhood absence epilepsy treatment market.

Segment Covered

The report on global childhood absence epilepsy treatment market covers segments such as drug, and disease type. On the basis of drug, the sub-markets include valproate, ethosuximide, lamotrigine, and phase 2 drugs (CX-8998 and cannabidiol oral solution). On the basis of disease type, the sub-markets include atypical absence seizures and typical absence seizures.

Companies Profiled:

The report provides profiles of the companies in the market such as Teva Pharmaceutical Industries Ltd., AbbVie, Insys Therapeutics, GlaxoSmithKline plc, Pfizer Inc. and Cavion, Inc.

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of childhood absence epilepsy treatment market. Moreover, the study highlights current market trends and provides forecast from 2019-2025. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.